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ART ICLE Open Ac ce s s
1q21.1 distal copy number variants are associated
with cerebral and cognitive alterations in humans
Abstract
Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple
neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a
high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain
structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-
CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088
non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized
methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only)
between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects
of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and
cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct
cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and
somewhat larger in deletion carriers—the latter potentially mediated by ICV or cortical surface area. These results shed
light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on
specific brain structures and effect on cognitive function.
Introduction
Inter-individual differences in brain structure are
highly heritable1, but identifying the genes that con-
tribute to brain development is challenging. Genome-
wide association studies (GWAS) of brain anatomical
structures indicate the influence of many single-
nucleotide polymorphisms (SNPs) with small effect
sizes2,3, but the links to brain function remain weak.
Evidence is emerging that some rare copy number var-
iants (CNVs)—that is, regions of the genome that are
either deleted or duplicated—are associated with both
substantial brain size and shape differences; for example,
the 7q11.234,5, 22q11.26,7, 15q11.28–11 and 16p11.2
proximal12–14 and distal CNVs15. Many of these CNVs
also have a wide-ranging phenotypic impact, including
poorer cognitive abilities8,16–18 and increased risk of
neurological or neurodevelopmental disorders. The
strong impact of these CNVs on brain structure
and behaviour make them valuable for studies of the
molecular mechanisms contributing to aberrant human
neurodevelopment.
The 1q21.1 distal CNV has a known large effect on head
circumference, as evident from a high prevalence of micro-
and macrocephaly in deletion and duplication carriers,
respectively19–21. This, along with its position in a region
that is rich in genes unique to the human lineage (i.e. absent
in primates)22,23, makes the 1q21.1 distal CNV particularly
interesting for the study of aberrations in human brain
structure. However, its relatively low frequency, 1 in ~3400,
(deletions) and 1 in 2100 (duplications)8,16, has hampered
the study of its effects on brain structure.
1q21.1 distal deletion and duplication carriers are both
at higher risk for several neurodevelopmental disorders
including schizophrenia24,25, intellectual disability (ID),
developmental delay, speech problems, autism spectrum
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disorders, motor impairment19,26–28 and epilepsy26,29, in
addition to the separate risk for the duplication carriers
for ADHD30, bipolar disorder and major depression31,32.
Further, general cognitive ability (IQ) was lower in car-
riers in a small clinical study19 and in the UK Biobank33.
In addition, 1q21.1 distal CNVs display a positive dose
response on head circumference19–21, height and
weight34,35 and are associated with various somatic dis-
eases and traits, including bone and muscle deviations34
and cataract36 (deletion only), diabetes36 (duplication
only) and heart disease36–39 (both). Conversely, several
studies report carriers without any clinically evident
phenotypes19,38 and considerable heterogeneity40,41, sug-
gesting incomplete penetrance and variable expressivity.
The Df(h1q21)+/− mouse, deleted in the syntenic 1q21.1
distal region, displays some phenotypes similar to human
CNV carriers, including reduced head-to-tail length and
altered dopamine transmission in response to psychosti-
mulants, as seen in people with schizophrenia42.
The 1q21 region in humans is rich in low copy number
repeats20,43 and contains several recurrent CNVs with
differing breakpoints21,37. Thus, gene estimates vary, but
the core interval encompasses at least 12 protein-coding
genes including several human-specific genes such as
HYDIN221,37, NOTCH2NLs22,23 and the DUF1220/Old-
uvain domain-containing NBPF-encoding genes44–46—the
two latter were recently shown to have evolved as a two-
gene unit47. Particularly interesting in the context of brain
development are the recently characterized NOTCH2NL
genes, absent in human’s closest living relatives and
shown to prolong cortical neurogenesis22,23.
Despite the strong effects on neurodevelopmental traits
and disorders, the impact of the 1q21.1 CNVs on human
brain structure is largely unknown. Here, we present the
first large-scale systematic neuroimaging study of 1q21.1
distal CNV carriers, investigating brain structure in
>37,000 individuals including 28 deletion and 22 dupli-
cation carriers. We mapped the effect of the 1q21.1 distal
CNV on subcortical volumes, intracranial volume (ICV)
and global and regional measures of mean cortical
thickness and surface area. We investigated variation in
cognitive task performance and supplemented with
exploratory mediation analysis of the brain on cognition
in the UK Biobank. Given prior findings19–21,48, we
explored a dose-dependent effect of copy number on
brain structures and decreased cognitive performance for




The brain structural sample comprises a total of 39
cohorts with genotyping and magnetic resonance imaging
(MRI) data—38 from the ENIGMA-CNV consortium in
addition to a subsample of the UK Biobank49 (project ID
#27412). Demographic characteristics for each cohort are
described in Supplementary Table 1 with a reference to
participants’ collection and datasets including individual
inclusion and exclusion parameters. Extended informa-
tion on diagnosis and family information can be found in
Supplementary Note 1 and age distribution of the cohorts
in Supplementary Fig. 1. All participants gave written
informed consent and sites involved obtained ethical
approvals. The main 1q21.1 distal sample consisted of 28
deletion carriers, 22 duplication carriers and 37,088 non-
carriers (Table 1) from 13 different datasets and 15 scan-
ner sites with various ascertainments (family, clinical and
population studies, case–control study for psychiatric
disease) collected up until 30 September 2019. Non-
carriers were defined as having no CNVs known to cause
neurodevelopmental diseases (as defined in Supplemen-
tary Table 2). In the meta-analysis, an independent Ice-
landic sample from deCODE Genetics consisting of two
deletion carriers and five duplication carriers in addition
to 1150 non-carriers was added.
Genotyping and QC
The genotypes were obtained by genotyping with
commercially available platforms, performed at partici-
pating sites for each cohort (Supplementary Table 1).
Individuals were excluded exclusively based on quality
control (QC) parameters from the CNV calling. No
exclusion was done due to ancestry in the primary ana-
lysis, but the effect of ancestry was evaluated in a separate
analysis (see below).
CNV calls and validation in the core ENIGMA-CNV sample
Almost all cohorts had CNVs called and identified in a
unified manner as described previously15. In brief, CNVs
were called using PennCNV50 and appropriate population
frequency (PFB) files and GC (content) model files
(Supplementary Table 3 and Supplementary Notes 2 and
3). Samples were filtered and CNVs identified based on
standardized QC metrics15 (Supplementary Notes 2 and
3). The 1q21.1 distal region was well covered by all arrays
(Supplementary Fig. 2). CNVs overlapping the region of
interest (1q21.1 distal and 1q21.1 distal and proximal)
were identified with the R package iPsychCNV, visualized
and manually inspected.
Image acquisition and processing
All brain measures were obtained from structural T1-
weighted MRI data collected at participating sites around
the world and analysed with the standardized image ana-
lysis, FreeSurfer, quality assurance and statistical methods
as per the harmonized neuroimaging protocols developed
within ENIGMA23 and ENIGMA3 (http://enigma.ini.usc.
edu/protocols/imaging-protocols/). Further detail on data
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processing is provided in Supplementary Note 4. Details
on study, scanner, vendor, field strength, sequence,
acquisition parameters and FreeSurfer versions used are
outlined in Supplementary Table 4.
Statistical analysis
Imaging data processing and CNV calling were per-
formed locally and de-identified CNV and imaging data
were provided for a central mega-analysis. One of a pair
of duplicates was kept. Relatives were removed from
the sample used for the main analysis. In addition, we
conducted a number of sensitivity analyses to test the
robustness of the results (Supplementary Note 5 and
Supplementary Tables 5–8). Individuals with a mini-
mum overlap of 0.4 to regions with known pathogenic
CNVs (Supplementary Table 2) were excluded from the
analysis regardless of copy number status as were indi-
viduals from scanner sites without 1q21.1 distal CNV
carriers.
Brain measures were normalized in R v3.3.2 by an
inverse normal transformation of the residual of a linear
regression on the phenotype correcting for covariates as
done previously15. For the primary analysis, covariates
were age, age2, sex, scanner site and ICV. In the analysis of
ICV, ICV was not included as a covariate. These final
covariance-corrected values were used in downstream
analysis and are reported for each measure. For compar-
ison between groups, normalization was carried out
including only the groups addressed (deletion and non-
carriers, duplications and non-carriers) except for the
deletion versus duplication comparison, where values
from normalization of the entire dataset were used due to
the low numbers.
For the copy number dosage effect analysis (i.e. the effect
on brain structure of 1q21.1 distal copy number variation),
a linear regression on the copy number status of the indi-
viduals (deletion= 1, normal= 2, duplication= 3) was
performed using the following model: covariance-corrected,
Table 1 Demographic data.
ENIGMA-CNV deCODE
del nc dup P del nc dup P
n 28 37,088 22 2 1150 5
Sex, male (%) 15 (54%) 17,912 (48%) 9 (41%) 1 (50%) 511 (44%) 2 (33%)
Age (mean (SD)) 41.7 (19.0) 61.1 (12.8) 55.4 (12.7) <0.001 53.5 (2.1) 44.8 (12.4) 46.4 (16.5)
Children (age <18 years) 4 (14%) 665 (1.8%) <0.001 0 0 0
Known diagnosis (%) 11 (39.3%) 2424 (6.5%) 7 (32%) <0.001 238 (21%) 2 (40%)
Disease type (%)
ADHD 1 (~0%) 181 (16%) 2 (40%)
Autism 2 (0.2%)
Bipolar disorder 7 (0.6%)
Clinically recruited (no diagnosis) 6 (21.4%) 4 (18%)
Dyslexia 1 (3.6 %)
F-ICD-10 diagnosis (UK Biobank) 858 (2.3%) 1 (4%)
G-ICD10 diagnosis (UK Biobank) 1 (3.0%) 1439 (3.8%) 1 (4%)
MDD 1 (~0%)
Multiple diagnosesa 2 (7.2%) 1 (4.5%)
Persistent depressive disorder 1 (~0%)
SCZ 1 (3.6) 124 (0.3) 48 (4.2%)
Scanner sites 11 15 8 2 2 1
Datasets 9 13 7 1 1 1
ADHD attention deficit disorder, clinically recruited in clinical NDD study but without a diagnosis, MDD major depressive disorder, SCZ schizophrenia, del deletion
carrier, nc non-carriers, dup duplication carrier, P P value, AvPD avoidant personality disorder, OCD obsessive-compulsive disorder, DPD dependent personality
disorder, STPD schizotypal personality disorder, NS non-significant.
P value is based on a χ2 test for categorical values and ANOVA for continuous values.
aFirst deletion carrier: agoraphobia, AvPD, OCD, DPD, other substance-related disorder, conduct disorder. Second deletion carrier: specific phobia, social phobia, MDD,
AvPD, STPD. Duplication carrier: social phobia, OCD, MDD, AvPD.
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normalized brain measure ~ copy number (deletion= 1,
non-carrier= 2, duplication= 3). For comparison between
groups, a two-sample, two-sided t test assuming equal
variance in all carrier/non-carrier groups was employed
(R v3.3.2) where deletion or duplication carriers were
compared either to each other or to non-carriers. To cor-
rect for the multiple comparisons, we calculated the num-
ber of independent outcome measures through the spectral
decomposition of a correlation matrix using MatSpDlite
(https://neurogenetics.qimrberghofer.edu.au/matSpDlite/)
of the three global, seven subcortical and 68 regional cor-
tical measures. Based on the ratio of observed eigenvalue
variance to its theoretical maximum, the estimated
equivalent of independent measures was 36. Thus, we set
the significance threshold at α= 0.05/36= 0.0014. We
report the uncorrected P values throughout the manuscript.
Effect size is calculated as the absolute effect size (the
difference in mean between the two copy number groups
in the t test—which, in this case, equals Cohen’s D as the
standard deviation of the normalized brain measures is
one) and the estimate of beta in the linear regression.
Plots were generated using R library ggplot2 v2.2.151.
Regional cortical visualization was done with the R
package ggseg v1.5.1.
In a novel analysis, the independent Icelandic data were
processed and analysed as the main dataset. We meta-
analysed the results using the R package metafor v2.0.0, as
previously15.
Cognitive task performance data
We downloaded behavioural performance measures
on seven cognitive tests (the pairs matching task, the
reaction time task, reasoning and problem-solving tests,
the digit span test, the symbol digit substitution test and
the trail making A and B tests) from the UK Biobank
repository, performed by at least 10% of the participants.
The results were processed following the general
approach by Kendall et al.16. For more details, see
Supplementary Note 6. For the analysis of the seven
cognitive measures, we set the significance threshold
to α= 0.05/7= 0.007.
Mediation analysis
Mediation analyses were done with the R package
mediation v4.4.7. Brain measures were normalized as
described above and cognitive tasks were corrected for
age, age2 and sex prior to input into the analysis. We
report the proportion of the total effect of the CNV on
cognitive task performance mediated by the brain mea-
sures (‘path ab’/‘path c’), with P values calculated
through quasi-Bayesian approximation using 5000 simu-
lations. We set the significance threshold at α= 0.05/
((2+ 4) × 6)= 1.4 × 10−3 given the test of two structures
for deletion and four for duplication carriers on six
cognitive tests. The digit span test was excluded since no
1q21.1 CNV carriers had results from both this cognitive
test and brain structural data.
Results
Sample characteristics
The main 1q21.1 distal (146.5–147.4Mb, hg19) brain
structural dataset consisted of 28 deletion and 22 dupli-
cation carriers and 37,088 non-carriers (derived from the
same scanner sites as the CNV carriers) from ENIGMA-
CNV and UK Biobank (Table 1, separate demographics in
Supplementary Table 9). The age of CNV carriers was
lower (41.7 ± 19.0 (deletions), 55.4 ± 12.7 (duplications),
respectively) than that of non-carriers (61.1 ± 12.1)
(Table 1). Eleven deletion carriers and seven duplication
carriers had a known neurological, neurodevelopmental
or psychiatric diagnosis or had been recruited in a clinical
CNV study. The remaining carriers either did not have an
established diagnosis or were recruited in studies from
which diagnostic information was unavailable (Table 1
and Supplementary Table 10). Of the 37,088 non-carriers,
6.5% (2425) had an established neurological, neurodeve-
lopmental or psychiatric disorder.
1q21.1 distal CNV associated with global cortical surface
structures
For our main dataset, there was a significant positive
association between the number of 1q21.1 distal copies
and ICV (β= 1.47, P= 2.8 × 10−25) as well as cortical
surface area (β= 0.81, P= 1.1 × 10−8) (Fig. 1 and Sup-
plementary Table 5) at a significance threshold of P <
0.0014 after correction for age, age2, sex, scanner site
and ICV. In contrast, a significant negative copy number
dosage effect was identified for the caudate (β=−0.49,
P= 6.9 × 10−4) and hippocampal volumes (β=−0.56,
P= 1.3 × 10−4). T tests indicated a decrease in ICV
(Cohen’s D=−1.84 (−17%), P= 1.6 × 10−22) for dele-
tion carriers and an increase for duplication carriers
(Cohen’s D= 0.90 (+10%), P= 2.3 × 10−5), respectively,
compared to non-carriers (Supplementary Table 6). For
a raw value plot of ICV, see Supplementary Fig. 3. The
cortical surface area dosage effect was primarily driven
by the deletion carriers with a significantly lower total
cortical surface area (Cohen’s D=−1.13 (−23%), P=
2.1 × 10−9) and the dosage effect on caudate and hip-
pocampus was primarily driven by duplication carriers
with significantly smaller caudate (Cohen’s D=−0.71
(−16%), P= 0.0012) and hippocampal (Cohen’s D=
−0.92 (−15%), P= 4.1 × 10−5) volumes than non-
carriers (Fig. 1 and Supplementary Table 7). Adding an
independent Icelandic dataset with two deletions, five
duplications and 1150 non-carriers (Table 1) in a meta-
analysis strengthened the majority of the dosage results
(Supplementary Fig. 4 and Supplementary Tables 11 and 12)
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and revealed additional significant between-group differ-
ences in nucleus accumbens, caudate and putamen (Sup-
plementary Table 12).
A number of sensitivity analyses were run on the main
dataset, namely:
(a) Matching each carrier with one non-carrier for age,
sex, scanner site and ICV or age, sex, scanner site;
(b) including only: (i) non-affected individuals
(i.e. excluding individuals with a known
neurodevelopmental or neurological disorder
Fig. 1 Cortical surface area and ICV show a positive dosage effect and caudate and hippocampus a negative dosage effect to copy
number in the 1q21.1 distal region in our main sample (ENIGMA-CNV and UK Biobank). Boxplots of subcortical volumes, cortical surface area
and mean cortical thickness and ICV are shown. Deletion carriers (del) in red, non-carriers (nc) in grey and duplication carriers (dup) in blue,
respectively. The normalized brain values are presented. Boxplots represent the mean. Copy number dosage effect is noted at the bottom of each
panel. Significant differences after correction between groups are noted as *P < 0.0014, **P < 0.00014, ***P= 0.000014. Centre line represents the
median, box limits are the upper and lower 25% quartiles, whiskers the 1.5 interquartile range and the points are the outliers. All analyses were
corrected for age, age squared, sex, scanner site and ICV (except for ICV).
Sønderby et al. Translational Psychiatry          (2021) 11:182 Page 5 of 16
Content courtesy of Springer Nature, terms of use apply. Rights reserved
diagnosis; (ii) adults (age ≥ 18); (iii) non-affected
adults; (iv) children (age < 18); (v) ENIGMA-CNV
or (vi) UK Biobank;
(c) controlling for ancestry;
(d) excluding ICV as a covariate or;
(e) including first- and second-degree relatives (see
Supplementary Note 5 for methods).
These analyses validated the overall effects (Supple-
mentary Tables 5 and 6).
The 1q21.1 distal CNV is associated with regional brain
structures
The largest dosage effects for the regional cortical sur-
face area were found in the frontal lobes followed by the
cingulate cortex—with additional significant effects in
three regions of the parietal and temporal lobes (Fig. 2 and
Supplementary Table 7). Likewise, through t tests, the
largest effects in both deletion and duplication carriers in
comparison to non-carriers were observed in the frontal
and cingulate cortices (Fig. 2 and Supplementary Table 8).
For regional cortical mean thickness, we identified sig-
nificant negative dosage effects in the superior temporal
region and significant positive dosage effects for the
pericalcarine region (Fig. 2 and Supplementary Tables 7
and 8). Similarly, significant increases in mean cortical
thickness were observed in deletion carriers versus non-
carriers in the pars triangularis and superior temporal
regions and a significant decrease in the pericalcarine
region (Fig. 2 and Supplementary Table 8). All regional
results were corrected for age, age2, sex, scanner site and
ICV. Sensitivity analyses similar to those performed for
subcortical regions confirmed the robustness of the
results (Supplementary Tables 7 and 8).
1q21.1 distal CNV associated with cognitive performance
and mediation by brain structures
Deletion and duplication carriers had different cognitive
profiles in comparison to non-carriers when testing for
association in seven different neuropsychological tests
available from the full UK Biobank sample: deletion car-
riers had significantly poorer performance in three tests:
symbol digit substitution, trail making B and pairs
matching, while duplication carriers had significantly
poorer performance in two tests: reaction time and the
reasoning and problem-solving task (Table 2).
Testing the effect of brain structures on cognitive tests
in UK Biobank participants, larger ICV and total surface
area were associated with better performance on almost
all tests (Table 3 and see Supplementary Table 13 for
sample size details). A larger hippocampus was associated
with better performance for symbol digit substitution,
trail making A and B (Table 3) and a larger caudate was
associated with higher performance on the trail making
A (Table 3).
Fig. 2 Results from the t tests and linear regression of 1q21.1 copy number variation on regional cortical surface area and cortical
thickness. First and third rows: Effect sizes (Cohen’s d for the t tests, beta coefficient for the dosage/linear regression). Second and fourth rows:
Statistical significance in –log 10 of the P value. Significant areas in rows 1 and 3 are marked with black lines with increasing thickness for increasing
significance (P < 0.0014). The column names indicate the comparisons with del= deletion carriers, nc= non-carriers, dup= duplication carriers.
All measures were corrected for age, age2, sex, scanner site and ICV.
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Next, we tested whether the brain structures sig-
nificantly associated with 1q21.1 distal CNV carriers
might mediate the effect of the CNV on cognition. For
two of the three tests associated with deletion carrier
status, there were significant mediation effects (sig-
nificance threshold 1.4 × 10−3): cortical surface area and
ICV accounted for 5 and 10%, respectively, of the poorer
performance of deletion carriers on symbol digit sub-
stitution, and 7 and 17%, respectively, of their poorer
performance on the trail making B test (Table 3).
Discussion
Our main finding was a significant positive dosage effect
in humans of 1q21.1 distal copy number on ICV and
cortical surface area, with the largest differences in frontal
and cingulate cortical surface area. We also identified a
significant negative dosage effect on caudate and hippo-
campal volumes. A number of sensitivity analyses con-
firmed the robustness of the results. Both 1q21.1 distal
deletion and duplication carriers showed poorer cognitive
performance, although on different tests, with an indica-
tion that decreased ICV/cortical surface area might
mediate the effect in deletion carriers.
The 1q21.1 distal CNV causes copy dosage effect on brain
structures
We found a strong effect of the 1q21.1 distal CNV on
the total cortical surface area, while no overall effect on
mean cortical thickness was observed. A specific increase
in the size of the cortical surface area with little effect on
cortical thickness is observed throughout mammalian
evolution including the primate lineage leading to
humans52. This possibly reflects that cortical thickness
and surface area appear to be driven by distinct genetic
processes53. This pattern may be the result of an increased
number of symmetric or self-renewing cell-division
cycles, leading to an expansion of the neural progenitor
pool and subsequently to an increase in the number of
cortical neurons—in line with the radial unit hypothesis52.
Interestingly, although not significant, mean cortical
thickness tended to decrease in deletion carriers in the
frontal cortical surface areas with the highest effect sizes,
resembling a pattern found in lissencephaly54. This could
suggest that large regional decreases in cortical surface
area correlate inversely with mean cortical thickness.
The biomechanical forces of brain growth are thought to
form the expansion of the cranium so that the skull grows
in harmony with the expanding brain55. Thus, the positive
copy number dosage effect on cortical surface area may
directly trigger the effect on head circumference19–21 and
ICV of 1q21.1 distal carriers due to modifications in
pressure. Altered mechanical pressure might also cause
the negative copy number dosage effect on the hippo-
campus and caudate volumes, effects on subcortical
volumes also observed in a UK Biobank exploratory study
on six individuals with a 1q21.1 distal duplication56.
Human-specific genes may affect the cortical surface area
and cross-species effects
The positive copy number dosage effect on brain
structure with the same direction as for weight and
height34,35 likely results from altered gene expression as
observed in 1q21.1 distal CNV cell lines48. In an inde-
pendent experiment on fetal tissue, we also observed
dynamic expression patterns of the genes in the 1q21.1
interval consistent with potential roles in cortical neuro-
genesis and development (Supplementary Note 7 and
Supplementary Figs. 5 and 6).
GWAS based on the hg19 genome assembly have not
identified hits in the 1q21.1 genomic region for ICV57,
total cortical or regional surface area53,58. Assembly of the
1q21.1 region59 and thus gene discovery is complicated
due to the presence of numerous low copy number
repeats20,43 and has been faulty until the GRCh38 genome
Table 2 1q21.1 CNV deletion and duplication carriers show deficits in specific cognitive functions.
Test Suggested domain n del vs. nc dup vs. nc
del nc dup Cohen’s D (SE) P Cohen’s D (SE) P
Pairs matching Working memory 119 468,709 186 −0.36 (0.09) 7.3E− 05** 0.03 (0.01) 0.7
Reaction time Simple processing speed 115 464,648 181 −0.12 (0.06) 0.18 −0.23 (0.07) 2.1E− 03
Reasoning and problem solving Fluid intelligence 29 154,490 71 −0.48 (0.19) 9.2E− 03 −0.33 (0.12) 5.3E− 03
Digit span Numeric memory 12 47,569 27 −0.27 (0.14) 0.36 0.14 (0.07) 0.47
Symbol digit substitution Complex processing speed 24 111,900 28 −0.78 (0.2) 1.4E− 04** 0.04 (0.02) 0.83
Trail making A Visual attention 23 98,495 27 −0.29 (0.15) 0.16 −0.14 (0.07) 0.45
Trail making B Visual attention 23 98,494 27 −0.87 (0.21) 3.1E− 05*** −0.19 (0.1) 0.33
n sample size, del deletion carriers, dup duplication carriers, nc non-carriers, SE standard error, P P value.
Multiple comparison-corrected significant findings (P < 0.007) are indicated in bold and with *<0.007, **<0.0007 and ***<0.00007.
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assembly. This may explain the lack of GWAS hits in
the region.
Candidates for a dosage-dependent amplifier of the
CNV-associated brain phenotypes are the recently iden-
tified human-specific NOTCH2NL genes that confer
delayed neuronal differentiation and increased progenitor
self-renewal22,23—in line with the radial unit hypothesis52.
The areas with the highest regional effect sizes overlap
with the areas of the highest expression of NOTCH2NLA
and C in utero22 in concordance with an early
Table 3 Mediation analysis of brain structures over the association between 1q21.1 distal CNV carrier status and
performance in the cognitive tasks in the UK Biobank.
Path B—effect of brain structure
on cognition
Deletion Duplication
Estimate (SE) P Prop. mediated P Prop. mediated P
Pairs matching
Caudate 0.0023 (0.0053) 0.66 3.5E− 03 0.85
Hippocampus 0.005 (0.0052) 0.34 9.8E− 03 0.68
SurfArea 0.031 (0.0055) 1.9E− 08 −0.07 0.65 −4.4E− 03 0.9
ICV 0.027 (0.0054) 4.3E− 07 −0.12 0.64 −0.07 0.51
Reaction time
Caudate −0.0016 (0.0054) 0.77 −2.3E− 03 0.67
Hippocampus 0.01 (0.0053) 0.053 0.01 0.04
SurfArea −0.0095 (0.0056) 0.091 0.02 0.13 7.3E− 04 0.78
ICV 0.029 (0.0055) 2.4E− 07 −0.1 0.07 −0.03 2.4E− 03
Reasoning and problem solving
Caudate −0.0059 (0.0091) 0.51 5.7E− 03 0.55
Hippocampus 0.0031 (0.0089) 0.73 −9.6E− 05 0.95
SurfArea 0.052 (0.0094) 2.6E− 08 0.06 0.250 −7.4E− 04 0.97
ICV 0.15 (0.0092) 3.7E− 59 0.25 0.24 0.18 0.04
Symbol digit substitution
Caudate 0.0011 (0.0077) 0.88 −4.2E− 03 0.83
Hippocampus 0.04 (0.0075) 6.5E− 08 −0.01 0.82
SurfArea 0.055 (0.0079) 3.8E− 12 0.05 2.4E− 03 6.9E− 04 0.99
ICV 0.066 (0.0079) 3.6E− 17 0.1 4.0E− 04 0.13 0.68
Trail making A
Caudate 0.034 (0.0084) 5.7E− 05 4.4E− 04 1
Hippocampus 0.04 (0.0081) 1.0E− 06 3.0E− 03 0.97
SurfArea 0.046 (0.0086) 1.1E− 07 0.09 0.19 1.1E− 03 0.98
ICV 0.059 (0.0085) 6.1E− 12 0.21 0.20 −0.01 0.99
Trail making B
Caudate 0.021 (0.0083) 0.012 −0.01 0.79
Hippocampus 0.04 (0.008) 6.9E− 07 −0.01 0.86
SurfArea 0.082 (0.0085) 6.4E− 22 0.07 8.0E− 04 8.9E− 03 0.92
ICV 0.11 (0.0084) 1.2E− 36 0.17 1.2E− 03 0.16 0.73
Path B is the effect of the brain structure on cognition overall including all 1q21.1 deletion and duplication carriers (4–13 CNV carriers in each group) and non-carriers
(n= 10,501–30,924; for exact numbers, see Supplementary Table 13). Each calculation included 5000 simulations.
The significance value for multiple comparisons (1.4 × 10−3) are in bold
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developmental effect such as the macrocephaly observed
in utero in a 1q21.1 distal duplication carrier38. Our
observations of a 2% reduced skull diameter in the 1q21.1
deletion mouse (Supplementary Fig. 7 and Supplementary
Notes 8 and 9) and recent findings of decreased total
brain volume focused on the temporo-parietal and sub-
cortical areas in the deletion mouse60 suggest that genes
overlapping between human and mice (nine of ten mice
genes are syntenic to the human region42) and not specific
to humans are also involved in the altered skull and brain
morphology. However, although diameter and volume are
not directly comparable, the 17% decrease in ICV in
human 1q21.1 deletion carriers would still point towards a
substantial role of human-specific genes or genes with
altered functions in comparison to mice. This underlines
the need for additional data to disentangle which specific
genes are involved in the skull and brain structural phe-
notypes. Of note, we also observed shorter bones overall
in the 1q21.1 deletion mice (Supplementary Fig. 8 and
Supplementary Note 9), expanding on previous head-to-
tail length data42, and lower bone mineral density in
female mice (Supplementary Fig. 9 and Supplementary
Note 9), which mirror bone characteristics from human
deletion carriers34 increasing the number of observed
cross-species effects between the 1q21.1 mice and human
1q21.1 deletion carriers.
1q21.1 distal CNV deletion and duplication carriers show
deficits in different cognitive functions
Our findings of widespread lower performance across
several tests in different domains for both carrier groups in
the volunteer-based UK Biobank sample are in line with
cognitive results from a recent study33 and support that
cognitive function in CNV carriers largely without a neu-
rodevelopmental diagnosis may still be compromised8,16.
Interestingly, the frontal and cingulate regions61, with the
greatest cortical effect sizes for distal 1q21.1, correlate
particularly with cognitive function and have gone through
the greatest expansion during human development and
evolution62. Our analyses indicated that the decreases in
cognitive task performance are partially mediated by the
observed differences in ICV and cortical surface area,
reflecting the positive correlation between brain volume
and intellectual function in line with previous findings63.
The decrease in performance for several cognitive tasks in
duplication carriers despite a larger ICV and cortical sur-
face area suggests that the positive correlations may only be
applicable within a certain narrower range. Interestingly,
recent genetic analysis of NOTCH2NL in archaic and
modern humans revealed ongoing adaptive evolution
towards a lower dosage of the protein64, suggesting nega-
tive effects of excessive NOTCH2NL protein.
Our brain structural findings in 1q21.1 distal CNV
carriers overlap with brain alterations in associated
disorders: for example, ADHD65, autism spectrum dis-
orders66, schizophrenia67, bipolar disorder68, major
depressive disorder69 and subtypes of epilepsy70, but the
exact overlaps differ between carrier groups. Of note,
1q21.1 distal deletion and duplication carriers display
direct, opposite effects on several brain structures, while
at risk for the same neurodevelopmental diseases. Other
pathogenic CNVs also display overlapping disease risk
and similar opposite copy number effects6,8–15 including
effects on the cortical surface area in 22q11 and 16p11.2
proximal CNV carriers6,12–14. These CNVs impact dif-
ferent genes, but may converge on the same downstream
pathways altering cortical surface area formation, similar
to what has been reported for behavioural and neuro-
cognitive phenotypes28.
This also suggests that other risk factors interplay to
cause disease. It also supports that subgroups within
neurodevelopmental disorders can be defined based on
genetic profile and brain structural differences.
We demonstrate large effects of 1q21.1 distal CNVs on
brain structure and cognition in humans including a
mediation effect. These findings provide insight into
molecular mechanisms involved in critical stages of
human brain development and mapping of gene dosages
to brain structural fingerprints.
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